ATHAlterity TherapeuticsATH info
$0.00info6.67%24h
Global rank
Market cap$0
Change 7d28.00%
YTD Performance6.67%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Category
Business data

    Alterity Therapeutics (ATH) Stock Overview

    Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

    ATH Stock Information

    Symbol
    ATH
    Address
    350 Collins StreetMelbourne, VIC 3000Australia
    Founded
    -
    Trading hours
    -
    Website
    https://alteritytherapeutics.com
    Country
    🇦🇺 Australia
    Phone Number
    61 3 9349 4906

    Alterity Therapeutics (ATH) Price Chart

    -
    Value:-

    Alterity Therapeutics Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $0.003970913061822153
    N/A
    Market Cap
    $0
    N/A
    Employees
    11.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org